101-500 Dumps changes on daily basis, download daily

killexams.com LPI Certification concentrate on guides comprise of real test questions and replies. Exceptionally our 101-500 test prep are legitimate, Latest, and 2022 refreshed on an ordinary premise. Many applicants breeze through their 101-500 test with our genuine inquiries test prep. On the off chance that you like to appreciate achievement, you ought to download 101-500 Dumps.

Exam Code: 101-500 Practice exam 2022 by Killexams.com team
101-500 LPIC-1 exam 101

Course Outline: LPIC-101 Certified Linux Administrator

This course prepares students to take the 101 exam of the LPI level 1 certification. The Linux Professional Institute (LPI) is the go to certification body for vendor independent Linux certifications. This course covers fundamental Linux skills such as file management and manipulation, text processing, command line use, package management, filesystems, hardware, and many more. Students will feel confident taking the LPI LPIC-1 101 exam with in classroom assessments and practice exams.

Module 1: Work on the command line
 Role of command shell
 Shells
 Gathering system info
 Identifying the shell
 Changing the shell
 Shell prompts
 Bash: bourne-again shell
 Navigating the filesystem
 Help from commands and documentation
 Getting help within the graphical desktop
 Getting help with man $ info
 Bash: command line history
 Bash: command editing
 Bash: command completion
 Shell and environment variables
 Key environment variables Lab tasks
 Help with commands
 Linux shells
 Shell variables
 Bash history
 Aliases
Module 2: Use streams, pipes, and redirects
 File redirection
 Piping commands together
 Filename matching
 File globbing and wildcard patterns
 Brace expansion
 General quoting rules
 Nesting commands
 Gotchas: maximum command length
Lab tasks
 Redirection and pipes
 Wildcard file matching
 Shell meta-characters
 Command substitution
Module 3: Manage file permissions and ownership
 Filesystem hierarchy standard
 Displaying directory contents
 Filesystem structures
 Determining disk usage with df and du
 File ownership
 Default group ownership
 File and directory permissions
 File creation permissions with umask
 Changing file permissions
 Suid and sgid on files
 Sgid and sticky bit on directories
 User private group scheme
Lab tasks
 Navigating directories and listing files
 Disk and filesystem usage
 File and directory ownership and permissions
Module 4: Create, delete, find, and display files
 Directory manipulation
 File manipulation
 Deleting and creating files
 Physical unix file structure
 Filesystem links
 File extensions and content
 Which and type
 Whereis
 Searching the filesystem
 Alternate search method
 Manually installed shared libraries
Lab tasks
 Manipulating files and directories
Module 5: Work with archives and compression
 Archives with tar
 Archives with cpio
 The gzip compression utility
 The bzip2 compression utility
 The xz compression utility
 The pkzip archiving/compression format
Lab tasks
 Archiving and compression
 Using tar for backups
 Using cpio for backups
Module 6: Process text streams using filters
 Producing file statistics
 The streaming editor
 Replacing text characters
 Text sorting
 Duplicate removal utility
 Extracting columns of text
 Displaying files
 Prepare text for display
 Previewing files
 Displaying binary files
 Combining files and merging text
Lab tasks
 Text processing
 Processing text streams
Module 7: Search text files using regular expressions
 Searching inside files
 Regular expression overview
 Regular expressions
 Re character classes
 Regex quantifiers
 Re parenthesis
Lab tasks
 Pattern matching with regular expressions
 Extended regular expressions
 Using regular expressions with sed
Module 8: Perform basic file editing operations using vi
 Text editing
 Vi and vim
 Learning vim
 Basic vi
 Intermediate vi
Lab tasks
 Text editing with vim
Module 9: Create, monitor, and kill processes
 What is a process?
 Process lifecycle
 Process states
 Viewing processes
 Signals
 Tools to send signals
 Managing processes
 Tuning process scheduling
 Job control overview
 Job control commands
 Nohup and disown
 Uptime
 Persistent shell sessions with screen
 Using screen
 Advanced screen
Lab tasks
 Job control basics
 Process management basics
 Screen basics
 Using screen regions
Module 10: Use rpm, yum, and debian package management
 Managing software
 Rpm architecture
 Working with rpms
 Querying and verifying with rpm
 Installing debian packages
 Querying and verifying with dpkg
 The alien package conversion tool
 Managing software dependencies
 Using the yum command
 Yumdownloader
 Configuring yum
 The dselect $ apt frontends to dpkg
 Aptitude
 Configuring apt
Lab tasks
 Working with rpms on ubuntu
 Querying the rpm database
Module 11: Work with partitions, filesystems, and disk quotas
 Partition considerations
 Logical volume management
 Filesystem planning
 Partitioning disks with fdisk $ gdisk
 Resizing a gpt partition with gdisk
 Partitioning disks with parted
 Filesystem creation
 Filesystem support
 Unix/linux filesystem features
 Swap
 Selecting a filesystem
 Filesystem maintenance
 Mounting filesystems
 Mounting filesystems
 Managing an xfs filesystem
 Nfs
 Smb
 Filesystem table (/etc/fstab)
 Configuring disk quotas
 Setting quotas
 Viewing and monitoring quotas
Lab tasks
 Hot adding swap
 Accessing nfs shares
 Setting user quotas
Module 12: Linux boot process
 Booting Linux on pcs
 Grub 2
 Grub 2 configuration
 Grub legacy configuration
 Boot parameters
 Init
 Linux runlevels aliases
 Systemd local-fs.target and sysinit.target
 Runlevel implementation
 System boot method overview
 Systemd system and service manager
 Systemd targets
 Using systemd
 Shutdown and reboot
 System messaging commands
 Controlling system messaging
Lab tasks
 Command line messaging
 Messaging with talkd
 Boot process
 Grub command line
 Basic grub security
Module 13: Determine and configure hardware settings
 Managing Linux device files
 Hardware discovery tools
 Configuring new hardware with hwinfo
 Pc architecture and bus
 Dma $ irq
 Usb devices
 Usb configuration
 Configuring kernel components and modules
 Kernel modules
 Handling module dependencies
 Configuring the kernel via /proc/
 Kernel hardware info – /sys/
 /sys/ structure
 Random numbers and /dev/random
Lab tasks
 Adjusting kernel options
Module 14: linux fundamentals
 Unix and its design principles
 Fsf and gnu
 Gpl – general public license
 The linux kernel
 Components of a distribution
 Red hat linux products
 Suse linux products
 Debian
 Ubuntu
 Logging in
 Got root?
 Switching user contexts
Gathering login session info
Lab tasks
 Login and discovery
 Switching users with su

LPIC-1 exam 101
LPI LPIC-1 study
Killexams : LPI LPIC-1 study - BingNews https://killexams.com/pass4sure/exam-detail/101-500 Search results Killexams : LPI LPIC-1 study - BingNews https://killexams.com/pass4sure/exam-detail/101-500 https://killexams.com/exam_list/LPI Killexams : Best Linux Certifications

More than 20 years after Linus Torvalds developed Linux, the operating system remains a force in the computing industry. While Linux is not widely used on desktops (making up just over 2.4% of the overall desktop operating system market share in January 2019, according to NetMarketShare), it is extraordinarily strong on the web server side, where it enjoys a market share of almost 54%.

IT professionals invest considerable time learning about server computing for everything from installation, configuration, maintenance and virtualization to application support and security. This also means that many IT professionals are working with and around Linux operating systems daily, often alongside Windows and various UNIX OS brands as well.

The best of the Linux certifications vie for considerable mindshare among IT professionals and present an interesting mix of distribution- or brand-agnostic credentials alongside some pretty formidable vendor-specific credentials. There are multiple well-elaborated certification ladders available to those interested in learning, using, and mastering the Linux operating system environment and all the many bells and whistles it supports.

The results of a job search we conducted on several popular job posting sites show which Linux certifications employers are looking for when hiring new employees. While results vary from day to day (and job board to job board), this table reflects those Linux-related certifications that employers were seeking in the U.S.

Job Board Survey Results (in alphabetical order, by certification)

Certification

SimplyHired

Indeed

LinkedIn Jobs

Linkup

Total

GCUX (SANS GIAC) 30 30 55 12 127
Linux+ (CompTIA) 1,045 1,339 779 547 3,710
LPIC (LPI) 38 41 247 44 370
Oracle Linux OCA 27 31 33 12 103
Oracle Linux OCP 61 69 69 25 224
RHCA (Red Hat) 89 102 190 38 419
RHCE (Red Hat) 467 553 754 267 2,041
RHCSA (Red Hat) 417 504 667 241 1,829

We found that for nearly every certification category listed above, the number of national jobs postings mentioning that certification has increased, in some cases substantially, since we surveyed the same job sites a year ago. Linux system administrators and engineers can expect average earnings in the low $70s and upward, depending on the job role. PayScale lists $70,194 as the average salary for Linux system administrators ($52,000/low and $101,000/high). Glassdoor reports earnings for Linux system administrators averaging $68,884, Linux system engineers at $99,348 and senior Linux system engineers at $122,071.

GCUX: GIAC Certified Unix Security Administrator

The Global Information Assurance Certification (GIAC) program is part of SANS, a highly regarded source of instruction and research in the information security field. SANS also provides breaking news, operates a security alert service and serves on all kinds of government, research and academic information security task forces, working groups and industry organizations.

The SANS GIAC program encompasses 37 information security certifications across several categories, such as cyber defense, penetration testing, incident response and forensics, management, audit, legal, developer and industrial control systems. The GIAC Certified UNIX Security Administrator (GCUX) falls under its Cyber Defense category, and aims at professionals who install, configure, monitor, secure and audit both Unix and Linux systems.

GIAC certifications must be renewed every four years by earning 36 continuing professional experience (CPE) credits. Also, credential holders must pay a certification maintenance fee of $429 every four years.

GCUX Facts & Figures

Certification Name

GIAC Certified Unix Security Administrator (GCUX)

Prerequisites & Required Courses

None; SEC506: Securing Linux/Unix training recommended (classroom, on demand, self-study or private; $6,610)

Number of Exams

One exam (75 questions, two hours, minimum passing score 68%)

Cost per Exam

$1,899 without training (called a GIAC certification attempt; includes two free practice exams) $769 as part of a training course $769 retake fee $429 certification renewal

Exams administered by Pearson VUE.

URL

https://www.giac.org/certification/certified-unix-security-administrator-gcux

Self-Study Materials

Practice tests available on the GIAC exam preparation page (two tests included in exam fee; additional practice tests are $159 each). No GCUX-specific study guides found; GIAC recommends searching for self-study materials based on the GCUX objectives’ knowledge areas and getting practical experience.

Linux+ (CompTIA Linux+ Powered by LPI)

CompTIA exercises extraordinary certification clout at the entry level in many IT niches. This nonprofit has shown itself as willing to team up with more focused IT organizations, associations and consortia to combine their own market reach and visibility with niche smarts and subject matter expertise on loan from various partners.

One great example is the organization’s partnership with the Linux Professional Institute (LPI), which resulted in the CompTIA Linux+ Powered by LPI credential. This unique certification replaced the original CompTIA Linux+ certification in 2010 and uses the same two exams required for LPIC-1 certification.

As a result of this partnership, IT professionals who are serious about Linux can earn both the Linux+ credential and the LPIC-1 at the same time. Candidates must first earn the Linux+ credential and then submit a request to CompTIA asking that their results be sent to LPI to obtain the LPIC-1 certification. CompTIA exam records are confidential, so candidates must request that their records be forwarded to LPI when taking the CompTIA Linux+ Powered by LPI exams.

Earning the CompTIA Linux+ Powered by LPI requires candidates to pass two exams. The first covers system architecture, installation and package management, GNU and Unix commands, devices, file systems and standard file system hierarchies. The second exam digs into command shells, scripting and data management, user interfaces and desktops, administrative tasks and activities, basic system services, networking fundamentals and security topics. The CompTIA Linux+ Beta exam (XK1-004) closed as of October 22, 2018, though candidates who took the exam prior to the end date can still access those scores and apply a passing grade to their Linux+ certification. The replacement Linux+ 104 exam based on this beta exam will become publicly available in April of 2019.

Note that the Linux+ credential is valid for life.

CompTIA Linux+ Powered by LPI Facts & Figures

Certification Name

CompTIA Linux+ Powered by LPI

Prerequisites & Required Courses

None required

Recommended: CompTIA A+, CompTIA Network+ and 12 months of Linux administration experience

Number of Exams

Two exams: LX0-103 and LX0-104 (60 multiple-choice questions each, 90 minutes, 500 required out of 200 to 800 scale to pass). Note that the LX0-104 Beta exam is no longer offered as of October 22, 2018; the replacement 104 exam becomes publicly available in April of 2019.

Cost per Exam

$200 per exam; prices vary by geography

URL

https://certification.comptia.org/certifications/linux

Self-Study Materials

CompTIA maintains a list of training materials and additional study options, including links to study guides, exam crams, practice tests, online and classroom training, CertMaster, and more. Additional third-party reference and review materials can be found on Amazon.

LPI (Linux Professional Institute) Certifications

The Linux Professional Institute (LPI) started up in October of 1999, almost one decade after Linus Torvalds began his pioneering efforts on the Linux kernel. Since then, LPI has become one of the leading certification providers on Linux syllabus and technologies. Given the organization’s distribution-agnostic approach to Linux, it offers excellent coverage of a platform that’s available in many forms and flavors in today’s marketplace.

The LPI Certification (LPIC) program is available in three distinct levels:

  • LPIC-1Linux Administrator: A  junior-level Linux certification with no prerequisites. Candidates must pass two exams that cover basic Linux skills, including installing and configuring Linux on a workstation, working at the command line, performing basic maintenance tasks, and making LAN or internet connections. While you can obtain the LPIC-1 credential directly from LPI, candidates should consider obtaining the CompTIA Linux+ Powered by LPI credential first, which qualifies you for both the Linux+ and LPIC-1 credentials.
  • LPIC-2Linux Engineer: An advanced-level Linux certification that requires an active LPIC-1 certification. Candidates must pass two exams that cover significant Linux skills and topics. The first exam covers the kernel, system startup, file system and devices, advanced storage administration, network configuration, system maintenance and capacity planning. The second exam covers web services, file sharing, network client management, email services, system security and troubleshooting, and domain name servers.
  • LPIC-3Linux Enterprise Professional Certification: A senior-level Linux certification that requires an active LPIC-2 and passing any single exam in the 300 series. Valid exam IDs currently include 300: Mixed Environment303: Security, and 304: Virtualization and High Availability. The Mixed Environment exam covers Samba (domain integration, user and group management, name services, share configuration and so forth), plus OpenLDAP, and working with Linux and Windows clients. The Security exam covers network, operations and application security, as well as cryptography and access controls. High availability cluster storage and management, along with virtualization, are covered in the Virtualization and High Availability exam.

In addition to the LPIC-1, 2 and 3 credentials, LPI also offers an entry-level credential, the Linux Essentials Professional Development Certificate (PDC). Linux Essentials focuses on foundational skills, such as creating and running simple scripts, restoring compressed backups and archives, working with the command line, Linux operating system basics, FOSS, and users/groups and file permissions for public and private directories. Linux Essentials is a great way to get started while gaining the skills and knowledge needed for the more challenging LPIC credentials.

LPI’s newest certification is the LPIC-OT DevOps Tools Engineer, which recognizes the effective use of tools for collaboration during system and software development. There are no prerequisites, and the single exam lasts for 90 minutes and has 60 questions.

LPIC credentials are worthwhile for IT pros whose chosen Linux distributions do not warrant their own certification programs, and for those seeking broad, vendor- and distribution-neutral coverage of Linux topics, tools and technologies. They are popular among IT pros and in demand among IT employers.

LPIC-1, LPIC-2 and LPIC-3 Facts & Figures

Certification Name

LPIC-1: Linux Administrator

LPIC-2: Linux Engineer

LPIC-3: Linux Enterprise Professional

Prerequisites & Required Courses

LPIC-1: None, Linux Essentials recommended

LPIC-2: Active LPIC-1 certification

LPIC-3: Active LPIC-2 certification plus completion of one of the 300 series specialty exams

Training is recommended but not required

Number of Exams

LPIC-1: Exam 101-500 and Exam 102-500

LPIC-2: Exam 201-450 and Exam 202-450

LPIC-3: One of the 300 series exams: Mixed Environment (Exam 300-100)

Security (Exam 303-200)

Virtualization and High Availability (Exam 304-200)

Cost per Exam

$200 per exam. Exams administered by Pearson VUE. Linux ID required to register.

URL

http://www.lpi.org/our-certifications/summary-of-certifications

Self-Study Materials

Study guides, courseware knowledge packs, eLearning courses, exam crams, practice tests, online and classroom training, Linux Academy subscriptions and more are available at LPI exam Preparation, LPI Marketplace and Amazon.

Oracle Linux OCA & OCP

When Oracle bought Sun Microsystems in 2010, it acquired a rich and deep UNIX tradition. Oracle started phasing out Solaris almost immediately after finalizing the Sun acquisition.

Today, Oracle offers associate- and professional-level certifications based on Linux rather than harking back to any kind of UNIX roots. These certifications retain enough of their Sun roots, however, so that courses are not mandatory prerequisites to taking the exams for the two Oracle Linux certifications currently available.

As with other vendor-specific Linux certifications, Oracle’s are most appealing to those who work with or around that distribution, or who wish to work for employers who use those distributions.

OCA and OCP Facts & Figures

Certification Name

Oracle Certified Associate (OCA), Oracle Linux 5 and 6 System Administrator

Oracle Certified Professional (OCP), Oracle Linux 6 System Administrator

Prerequisites & Required Courses

OCA: No prerequisites. Recommended training: Oracle Linux S­­ystem Administration OCP: OCA Linux 5 and 6 System Administrator or Linux Administrator Certified Associate (now retired). Recommended training: Oracle Linux System Administration

Number of Exams

OCA: One exam, 1Z0-100 Oracle Linux 5 and 6 System Administration (150 minutes, 80 questions, 61% to pass) OCP: One exam, 1Z0-105 Oracle Linux 6 Advanced System Administrator (150 minutes, 97 questions, 61% to pass)

Cost per Exam

OCA: $245

OCP: $245

URL

https://education.oracle.com/oracle-linux/oracle-linux-administration/product_295?certPage=true

Self-Study Materials

Oracle offers online and in-class training for its credentials, with hit-or-miss coverage for them on the aftermarket. Start with Amazon searches — check exam IDs 1Z0-100 and 1Z0-105 to get a sense for what’s available.

Note: Though there is now an OCA and OCP exam available for Oracle Linux 7 System Administrator, Oracle has yet to announce this new certification or release the details of new Linux 7-based certification tests for OCA and OCP candidates.

Oracle Linux 6 Certified Implementation Specialist Certification

The Oracle Linux 6 Certified Implementation Specialist Certification is a certification available for those who sell, design, configure and implement Oracle Linux 6 solutions. Though any candidate can complete this certification, it is most typically achieved by Oracle partner implementation personnel with strong foundational experience in Linux and previous field experience implementing Linux 6.

Red Hat RHCSA, RHCE & RHCA

If there’s one major star in the vendor-specific Linux certification firmament, it’s got to be Red Hat. The company has major market presence and serious duration as a commercial provider of Linux platforms and technologies.

Red Hat offers a typical administrator, engineer, architect certification ladder. Unlike many other such programs, however, it offers highly regarded and valued credentials at each rung, along with demanding and hands-on oriented exams and an excellent training curriculum to match. All exams for the following Red Hat certifications are performance based and last two hours or longer.

The giveaway for Red Hat certifications is that all come with acronyms that start with RH, as follows:

  • Red Hat Certified System Administrator (RHCSA): This foundation certification vets essential skills in handling files, working at the command line and using system documentation, along with managing systems (boot up, identifying processes, start/stop virtual machines, controlling services), configuring storage partitions and logical volumes, and more.
  • Red Hat Certified Engineer (RHCE): This cornerstone certification is designed to test and validate the skills and knowledge necessary to work as a senior-level Linux system administrator. syllabus covered include advanced IP routing and services, managing runtime kernel behavior, working with iSCSI, automating maintenance tasks with shell scripts and working with networking services for Web, FTP, NFS, SMB, SMTP, SSH and more. An RHSCA is a prerequisite for the RHCE.
  • Red Hat Certified Architect (RHCA): Red Hat’s pinnacle certification offers two paths to certification, depending on which prerequisite advanced Red Hat certification credentials you have already completed: Red Hat Certified Enterprise Microservices Developers (RHCEMDs) and Red Hat Certified JBoss Developers (RHCJDs) can earn an RHCA in Enterprise Applications, and Red Hat Certified Engineers (RHCEs) can earn an RHCA in Infrastructure. In general, the five additional exams that must be passed to achieve the RCHA in either Infrastructure or in Enterprise Applications are specific to each area of specialization, though a few of the tests can be used to satisfy the five exam requirement in both RHCA tracks. A number of previously available certification exams have been discontinued for new RHCA candidates and renewals, though those exams can still be applied to the RHCA certification if you’ve already passed them. Find out more about discontinued exams that can be counted towards the RHCA credential on the RHCA page under the Candidate Guidance tab.

Because Red Hat Linux is widely used in the business world, the RHCA certification is an excellent choice for those interested in a more platform-focused path into the Linux world. Of course, for those who already work with or around Red Hat, it is a natural certification choice as well.

RHCSA, RHCE and RHCA Facts & Figures

Certification Name:

Red Hat Certified System Administrator (RHCSA)

Red Hat Certified Engineer (RHCE)

Red Hat Certified Architect (RHCA)

Prerequisites & Required Courses

RHCSA: No prerequisites Recommended training:

Windows system administrators: Red Hat System Administration I (RH124) (5 days, $3,400) and II (RH134) (4 days, $3,400)Linux/Unix Administrators, RHCSA Rapid Track Course (RH199) (4 days, $3,700)

RHCE: RHCSA credential Recommended training:

Same as for RHCSA, plus

Red Hat System Administration III (RH254) ($3,400)

RHCA:

RHCE-certified (Infrastructure track) – Candidates currently holding an RHCE certification must pass five additional exams from the Infrastructure track below.

RHCJD/RHCEMD-certified (Enterprise Applications track) – Candidates currently holding an RHCJD or an RHCEMD certification must pass five additional exams from the Enterprise Applications track below.

Number of Exams

RHCSA: One exam, EX200 Red Hat Certified System Administrator (RHCSA) exam (2.5 hours) RHCE: One exam, EX300 Red Hat Certified Engineer (RHCE) exam (3.5 hours) RHCA: Five exams total depending on whether you have already completed an RHCE certification (for the RHCA Infrastructure track), or an RHCEMD/RHCJD (for the RHCA Enterprise Applications track): An RHCE must pass five exams from the following list to achieve the RHCA in Infrastructure:

EX125 – Red Hat Certified Specialist in Ceph Storage Administration exam

EX210 – Red Hat Certified System Administrator in Red Hat OpenStack exam

EX220 – Red Hat Certified Specialist in Hybrid Cloud Management exam

EX236 – Red Hat Certified Specialist in Gluster Storage Administration exam

EX248 – Red Hat Certified Specialist in Enterprise Application Server Administration exam

EX270 – Red Hat Certified Specialist in Container Management (Retired)

EX276 – Red Hat Certified Specialist in Containerized Application Development (Retired)

EX280 – Red Hat Certified Specialist in OpenShift Administration exam

EX310 – Red Hat Certified Engineer in Red Hat OpenStack

EX318 – Red Hat Certified Virtualization Administrator exam

EX333 – Red Hat Certified Specialist in Security: Network Services exam (Retired)

EX342 – Red Hat Certified Specialist in Linux Diagnostics and Troubleshooting

EX401 – Red Hat Certified Specialist in Deployment and Systems Management exam (Retired)

EX403 – Red Hat Certified Specialist in Deployment and Systems Management exam

EX405 – Red Hat Certified Specialist in Configuration Management

EX407 – Red Hat Certified Specialist in Ansible Automation exam

EX413 – Red Hat Certified Specialist in Server Security and Hardening exam

EX415 – Red Hat Certified Specialist in Security: Linux exam

EX423 – Red Hat Certified Specialist in Directory Services and Authentication exam (Retired)

EX429 – Red Hat Certified Specialist in SELinux Policy Administration exam (Retired)

EX436 – Red Hat Certified Specialist in High Availability Clustering exam

EX440 – Red Hat Certified Specialist in Messaging Administration exam

EX442 – Red Hat Certified Specialist in Linux Performance Tuning exam

RHCSA: One exam, EX200 Red Hat Certified System Administrator (RHCSA) exam (2.5 hours) RHCE: One exam, EX300 Red Hat Certified Engineer (RHCE) exam (3.5 hours) RHCA: Five exams total depending on whether you have already completed an RHCE certification (for the RHCA Infrastructure track), or an RHCEMD/RHCJD (for the RHCA Enterprise Applications track): An RHCE must pass five exams from the following list to achieve the RHCA in Infrastructure:

EX125 – Red Hat Certified Specialist in Ceph Storage Administration exam

EX210 – Red Hat Certified System Administrator in Red Hat OpenStack exam

EX220 – Red Hat Certified Specialist in Hybrid Cloud Management exam

EX236 – Red Hat Certified Specialist in Gluster Storage Administration exam

EX248 – Red Hat Certified Specialist in Enterprise Application Server Administration exam

EX270 – Red Hat Certified Specialist in Container Management (Retired)

EX276 – Red Hat Certified Specialist in Containerized Application Development (Retired)

EX280 – Red Hat Certified Specialist in OpenShift Administration exam

EX310 – Red Hat Certified Engineer in Red Hat OpenStack

EX318 – Red Hat Certified Virtualization Administrator exam

EX333 – Red Hat Certified Specialist in Security: Network Services exam (Retired)

EX342 – Red Hat Certified Specialist in Linux Diagnostics and Troubleshooting

EX401 – Red Hat Certified Specialist in Deployment and Systems Management exam (Retired)

EX403 – Red Hat Certified Specialist in Deployment and Systems Management exam

EX405 – Red Hat Certified Specialist in Configuration Management

EX407 – Red Hat Certified Specialist in Ansible Automation exam

EX413 – Red Hat Certified Specialist in Server Security and Hardening exam

EX415 – Red Hat Certified Specialist in Security: Linux exam

EX423 – Red Hat Certified Specialist in Directory Services and Authentication exam (Retired)

EX429 – Red Hat Certified Specialist in SELinux Policy Administration exam (Retired)

EX436 – Red Hat Certified Specialist in High Availability Clustering exam

EX440 – Red Hat Certified Specialist in Messaging Administration exam

EX442 – Red Hat Certified Specialist in Linux Performance Tuning exam

EX450 – Red Hat Certified Specialist in Data Virtualization exam

RHCEMDs and RHCJD must pass five exams from the following list to achieve the RHCA certification in Enterprise Applications:

EX288 – Red Hat Certified Specialist in OpenShift Application Development exam

EX248 – Red Hat Certified Specialist in Enterprise Application Server Administration exam

EX276 – Red Hat Certified Specialist in Containerized Application Development exam (Retired)

EX280 – Red Hat Certified Specialist in OpenShift Administration exam

EX405 – Red Hat Certified Specialist in Configuration Management

EX407 – Red Hat Certified Specialist in Ansible Automation exam

EX421 – Red Hat Certified Specialist in Camel Development exam

EX427 – Red Hat Certified Specialist in Business Process Design exam

EX440 – Red Hat Certified Specialist in Messaging Administration exam

EX450 – Red Hat Certified Specialist in Data Virtualization exam

EX453 – Red Hat Certified Specialist in Fast-Cache Application Development exam

EX465 – Red Hat Certified Specialist in Business Rules exam

Cost per Exam

$400 each ($2,000 total RHCA exam costs)

URL

www.redhat.com/training/certifications/#certifications

Self-Study Materials

Red Hat skills assessments and other materials can be located on the training page. Red Hat Training includes multiple training options (online, classroom, self-paced, virtual, video and more). Red Hat Learning Subscription includes all online courses in one package; prices vary by geography, candidates can expect to pay $5,500 for a Basic Subscription and $7,000 for a Standard Subscription. Study guides are on Amazon.

Beyond the Top 5: More Linux certifications

Outside the top five Linux credentials and programs covered in this article, other Linux certifications may be worthy of your time and attention.

The Linux Foundation, a membership-based organization, promotes the development of the Linux kernel through collaboration, conferences and education. The organization’s small but respected certification program includes the Linux Foundation Certified System Administrator (LFCS) and the Linux Foundation Certified Engineer (LFCE).

IBM continues to offer a handful of Linux-related certifications. One certification of interest is the Certified Database Administrator, which continues to be in demand for those running DB2 on Linux, Unix and Windows systems.

Many industry experts, including Steven J. Vaughn-Nichols, a long-time user and expert on Linux and Unix operating systems, say that certifications can be an important ingredient in a job candidate’s qualifications. But interviewers should also pay close attention to how many Linux systems candidates have set up, managed or used to get a sense of the scale and scope of their experience.

In other words, when you see a web hosting service advertising for Linux jobs, they’re not looking for people who’ve installed and used Linux at home or in a small business setting; they’re looking for professionals who’ve set up and managed Linux in a highly distributed and virtualized data center environment, with lots of complex networking and services coming into the mix.

Tue, 11 Oct 2022 12:00:00 -0500 en text/html https://www.businessnewsdaily.com/10750-best-linux-certifications.html
Killexams : Grab 10% Yield With Laredo Petroleum Bonds
The word bonds on wooden cubes with office desktop. Business finance stock exchange

cagkansayin

Despite the big jump in oil prices this year, Laredo Petroleum (NYSE:LPI) shareholders have not seen a growth in their investment. While share prices have seesawed through the year, investors have lost 15% in the past year. Meanwhile, the company's high-yield debt has declined to slightly below par, which for its 2028 bonds, is creating coupon yields and a yield to maturity of greater than 10%.

Laredo Petroleum one year share price history

Seeking Alpha

Price and Yield of all Laredo Petroleum bond offerings

FINRA

An examination of Laredo's balance sheet reveals several impressive changes during the first six months of 2022. First, the company has managed to simultaneously build its cash balance while investing in its capital assets (property, plant, and equipment). In the first six months of 2022, Laredo managed to spend $150 million more on assets than what was depreciated. These investments should help the company increase production and subsequently revenue.

Laredo Petroleum Asset Section of Balance Sheet

SEC Q2 2022 10-Q

What may be more impressive is that Laredo has generated excess cash and invested in its assets while paying down long-term debt by more than $125 million, resulting in equity growth of more than $160 million. While other companies may use the increased business to take risky investments and leverage themselves further, Laredo wisely managed its resources to strengthen its balance sheet.

Laredo Petroleum Liability and Equity section of balance sheet

SEC Q2 2022 10-Q

From a profitability standpoint, Laredo seized the opportunity afforded by higher commodity prices and in its investments in assets to double its revenue and triple its operating income. These improvements translated to an explosion of operating cash flow by $350 million in the first six months of 2022 vs the same time period of 2021. It's important to recognize that derivative activity helped buoy the company's cash flow in 2021 but did not adversely impact Laredo's cash flow in 2022.

Laredo Petroleum Income and Profit Statement

SEC Q2 2022 10-Q

Laredo Petroleum operating cash flow

SEC Q2 2022 10-Q

Laredo was able to use its excess operating cash flow to increase its capital expenditures (hence the increase in net property, plant, and equipment) and still generate positive free cash flow of $250 million in the first six months of 2022. The increased free cash flow allowed Laredo to pay off its senior secured credit facility (a $105 million reduction in debt) and to pay off an additional $32 million in debt. Bondholders can be assured of their investment if the company continues to generate robust cash flow.

Laredo Petroleum Cash flow Uses

SEC Q2 2022 10-Q

In addition to Laredo's paying off its senior secured credit facility, the company is not facing a new debt maturity until January 2025 when nearly half of its $1.3 billion debt load comes due. Even if the credit markets are inaccessible to Laredo, the company's senior secured facility can be drawn up to $2 billion, proving the company with enough liquidity to cover its long-term debt obligations.

Laredo Petroleum Long Term Debt

SEC Q2 2022 10-Q

Laredo Petroleum senior secured debt capacity

SEC Q2 2022 10-Q

While one obvious risk to the company is energy prices, another is M&A. Should Laredo undertake a risky merger or acquisition involving further leverage, it could compromise the ability of the company to service its debt. The energy sector is littered with exact bankruptcies on the back end of a merger. Such an action by Laredo would have me seriously reconsidering my investment.

Due to Laredo already paying back some of its debt this year, investors should not expect significant price declines in its bonds as the company is expected to continue paying back debt.

CUSIP: 516806AG1

Price: $98.72

Coupon: 10.125%

Yield to Maturity: 10.44%

Maturity Date: 1/15/2028

Credit Rating (Moody's/S&P): B3/B

You can get an updated price of this bond by checking out its page on FINRA.

Fri, 14 Oct 2022 05:41:00 -0500 en text/html https://seekingalpha.com/article/4546614-laredo-petroleum-bonds-10-percent-yield
Killexams : LPI Makes Bullish Cross Above Critical Moving Average No result found, try new keyword!In trading on Wednesday, shares of Laredo Petroleum, Inc (Symbol: LPI) crossed above their 200 day moving average of $73.94, changing hands as high as $74.86 per share. Laredo Petroleum ... Wed, 05 Oct 2022 08:20:00 -0500 text/html https://www.nasdaq.com/articles/lpi-makes-bullish-cross-above-critical-moving-average Killexams : Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

MELBOURNE, Australia, Sept. 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited TLX Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma multiforme (GBM).

The primary objective of the IPAX-1 study was to evaluate the safety and tolerability profile of intravenous 131I-IPA administered concurrently with second line EBRT in patients with recurrent GBM. Secondary objectives were to determine optimal dosing, biodistribution and radiation absorption into the tumour, as well as assess preliminary efficacy through clinical and imaging-based assessment of tumour response.

Final data up to the completion of the post-study follow-up period confirms the study has met its primary objective, demonstrating the safety and tolerability profile of TLX101 at the dosing range tested. The study also delivered encouraging preliminary efficacy data for further evaluation, demonstrating a median overall survival (OS) of 13 months from the initiation of treatment in the recurring setting, or 23 months from initial diagnosis. Given that GBM has a median survival from initial diagnosis of 12-15 months, the overall survival improvement trend seen in this patient population clearly warrants further evaluation in a larger patient population.

Recurrent GBM is a highly aggressive cancer that progresses rapidly, and for which there are few effective treatment options. TLX101 is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1 (LAT-1), which is typically over- expressed in GBM. TLX101 has been granted orphan drug designation in the United States and Europe.

IPAX-1 Results Summary

10 patients were enrolled of whom 9 received the full study treatment dosing of ~2GBq (2000 MBq) of TLX101, either in the form of a single administration or one of two triple-fractionated regimens. The results demonstrated all dosing regimens, in combination with EBRT, were well tolerated:

  • Dosimetric analysis demonstrates that radiation exposure to key organs is well within acceptable safety limits.
  • The most frequent treatment emergent adverse events (TEAEs) were decreased lymphocyte count, fatigue, headache and hiccups, which occurred in three patients (30%), followed by decreased platelet count, diarrhea, cerebral oedema (swelling), and insomnia, which occurred in two patients (20%).
  • Except for cerebral oedema (swelling), a typical side-effect of radiation to the brain, adverse events were of low grade, did not show any trends or patterns and were clinically manageable, with a significant proportion deemed unrelated to therapy. The therapy was generally well tolerated by patients.
  • Overall survival (OS) was a median of 13 months, from initiation of therapy in the recurrent disease setting.
  • Of the nine patients who received conventional imaging, four (44%) exhibited stable disease at day 135 and two (22%) at day 180, determined by longitudinal imaging.
  • Two patients remain alive at the time of study report.

Dr. Colin Hayward, Chief Medical Officer at Telix said, "We are pleased to report this final outcome, which will be submitted for publication. We can reconfirm that TLX101 has demonstrated safety and tolerability profile and encouraging early efficacy data. The median overall survival of 13 months from initial treatment in the recurrent second line setting reinforces the validity of further investigation and dose escalation of TLX101 in patients with GBM. Due to the aggressive nature of this cancer and limited treatment options, we are experiencing a high level of interest in the follow-on study that Telix is now undertaking in newly diagnosed patients, as a front-line therapy in combination with standard of care treatment. In parallel we will continue to study TLX101 in the recurrent setting."

Dr Josef Pichler, Kepler University Hospital, Austria and Principal Investigator in the IPAX-1 study said, "When you consider that GBM has a median survival from initial diagnosis of 12-15 months, the potential benefit demonstrated in relapsed patients, in a second-line setting is encouraging. We are very motivated to continue to investigate TLX101 in a larger patient population in the planned Phase II IPAX-L (Linz) study underway at Kepler University Hospital, with the goal of collecting additional safety and efficacy data for TLX101 in in combination with EBRT in patients with relapsed-glioblastoma."

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange TLX. For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix's lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),[1] and by the Australian Therapeutic Goods Administration (TGA).[2] Telix is also progressing marketing authorisation applications for this investigational candidate in Europe[3] and Canada.[4]

Telix Investor Relations

Ms. Kyahn Williamson

Telix Pharmaceuticals Limited

SVP Corporate Communications and Investor Relations

Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release the disclosure committee of Telix Pharmaceuticals Limited.

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments.  Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our genuine results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's genuine results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.  

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.  

[1] ASX disclosure 20 December 2021.

[2] ASX disclosure 2 November 2021.

[3] ASX disclosure 10 December 2021.

[4] ASX disclosure 16 December 2020.

View original content to get multimedia:https://www.prnewswire.com/news-releases/final-ipax-1-study-data-confirms-safety-and-tolerability-profile-for-tlx101-preliminary-efficacy-data-301629030.html

SOURCE Telix Pharmaceuticals Limited

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Tue, 20 Sep 2022 11:31:00 -0500 text/html https://www.benzinga.com/pressreleases/22/09/n28941332/final-ipax-1-study-data-confirms-safety-and-tolerability-profile-for-tlx101-preliminary-efficacy-d
Killexams : Banks' cryptocurrency exposure sits at only 0.1%, study shows
Businessman is holding a bitcoin as part of a business network, Cryptocurrency blockchain connection, Technology and financial investment background concept.

KanawatTH

The total cryptocurrency exposures reported by 19 predominantly U.S. banks represented 9.4B euros ($9B), or a just 0.14% of total exposures, according to a exact study by the Basel Committee on Banking Supervision, the primary global standard setter for banking regulations.

That figure shrank to 0.01% across all 182 banks considered for the exercise, including those that did not report crypto exposure.

The study was based on a new crypto data collection template sent to a number of banks and designed to support the committee’s two documents on the prudential treatment of banks’ cryptoasset exposures it published in June 2021 and June 2022. Those two documents refer to the Basel Committee's efforts to toughen rules that would determine how depository institutions could enter crypto.

The primary crypto exposures featured bitcoin (BTC-USD) (31%) and ethereum (ETH-USD) (22%) as well as other instruments based on those tokens (35%), the study found. The reported exposures spanned an array of crypto-linked banking activities, such as clearing, lending, custody and market making. Most banks provided crypto custody or wallet services, followed by client trading of cryptos or crypto derivatives.

Given the speediness of the crypto market evolution, it's hard to discover whether some banks have under- or over-reported their crypto exposures.

With that being said, the results of the study, "while they are helpful in providing a broad indication of banks’ cryptoasset activity, should interpreted with a degree of caution,” the committee warned, also noting the small number of banks replying didn't help provide a more complete picture.

Banks of all sizes have increasingly deepened their involvement in the cryptosphere - despite a market downturn - as firms come to the realization that blockchain technologies (not necessarily the underlying crypto) could be "here to stay" amid growing interest and usage.

SVB Financial (NASDAQ:SIVB), Customers Bancorp (NYSE:CUBI), Metropolitan Bank (NYSE:MCB), Signature Bank (NASDAQ:SBNY), Bank of New York Mellon (NYSE:BK), BNP Paribas (OTCQX:BNPQF) (OTCQX:BNPQY) and Leumi (OTCPK:BLMIF) are among some of the banks that have taken part in the decentralized finance sector in exact months.

Recall BNY Mellon (BK) reportedly planned to introduce a crypto custody platform later in 2022 in a move that would allow its clients to hold both bitcoin (BTC-USD) and ether (ETH-USD) in digital wallets. And French lender BNP Paribas (OTCQX:BNPQF) (OTCQX:BNPQY) recently partnered with Metaco, a Swiss crypto infrastructure firm that specializes in crypto custody.

In August, the Federal Reserve introduced new guidelines for crypto-focused banks.

Fri, 30 Sep 2022 23:17:00 -0500 en text/html https://seekingalpha.com/news/3887562-banks-cryptocurrency-exposure-sits-at-only-01-study-shows
Killexams : Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Cellectar Biosciences

FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced it has been awarded $1.98 million in additional grant funding to expand its ongoing Phase 1 study of iopofosine I 131 (iopofosine) in children and adolescents with inoperable relapsed or refractory high grade gliomas (HGGs).

The grant was awarded by the National Institute of Health’s National Cancer Institute (NCI) based upon the initial signals of efficacy in the Phase 1 study, which is an international, open-label, dose escalation, safety study. The funding allows for an expansion from the Part 1a into the Part 1b portion of the company’s ongoing Phase 1 pediatric study. To accelerate development, the study is designed as a two-part approach. The currently ongoing Phase 1a is designed to determine the safety, tolerability, and initial efficacy of iopofosine in pediatric brain tumors whereas the Phase 1b is designed to identify the dose and dosing regimen that results in optimal efficacy. Previously announced preliminary data demonstrated therapeutic responses to iopofosine as evidenced by changes in multiple tumor parameters and patients experiencing extended progression free survival.

“The approximately $2 million non-dilutive grant funding from the NCI’s peer reviewed process is additional validation that iopofosine has shown encouraging potential in this very difficult to treat patient population. Unfortunately, patients with HGGs often have very poor prognoses, with limited treatment options,” said James Caruso, president and CEO of Cellectar. “We continue to be encouraged by the ability of iopofosine to cross the blood brain barrier, deliver sufficient radiation to the tumor and demonstrate early efficacy signals. We remain steadfastly committed to the thoughtful development of iopofosine in this devastating indication.”

Pediatric HGGs are a collection of aggressive brain and central nervous system tumor subtypes including diffuse intrinsic pontine gliomas, glioblastomas, astrocytomas and ependymomas. Children with these tumors have very poor prognoses, with typical progression-free survival of only a few months and a 5-year survival of less than 30%.

About iopofosine I-131
Iopofosine is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates iopofosine from many traditional on-market treatments. Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The company is currently investigating iopofosine in a global, open-label, pivotal expansion cohort in relapsed or refractory WM patients who have received at least two prior lines of therapy, including those who have failed or had a suboptimal response to Bruton tyrosine kinase inhibitors. The WM cohort will enroll up to 50 patients to evaluate the efficacy and safety of iopofosine for marketing approval. The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.

The Phase 1 pediatric study is an open-label, sequential-group, dose-escalation study to evaluate the safety and tolerability of iopofosine in children and adolescents with relapsed or refractory cancers, including malignant brain tumors, neuroblastoma, sarcomas, and lymphomas (including Hodgkin’s lymphoma). The Phase 1 study is being conducted internationally at seven leading pediatric cancer centers.

For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Forward-Looking Statement Disclaimer

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause genuine future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2021, and our Form 10-Q for the quarter ended March 31, 2022, when filed. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Contacts

Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com

Thu, 22 Sep 2022 01:33:00 -0500 en-US text/html https://finance.yahoo.com/news/cellectar-awarded-2-million-grant-123000121.html
Killexams : Virios Therapeutics Says Phase 2b Study Of IMC-1 In Fibromyalgia Fails To Meet Primary Endpoint No result found, try new keyword!(RTTNews) - Virios Therapeutics, Inc. (VIRI), a development-stage biotechnology company focused on chronic diseases, including fibromyalgia or FM, Monday said topline results from its Phase 2b ... Mon, 19 Sep 2022 00:30:00 -0500 text/html https://www.nasdaq.com/articles/virios-therapeutics-says-phase-2b-study-of-imc-1-in-fibromyalgia-fails-to-meet-primary Killexams : Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)

Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala® (mepolizumab), to US-sourced and EU-sourced reference product in normal healthy volunteers. The clinical study is a randomized, double-blind, parallel group, single-dose study that is expected to enroll approximately 207 healthy volunteers.

Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody that is administered subcutaneously with a syringe or autoinjector. Mepolizumab is currently indicated for the following conditions: 1) as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype, 2) as an add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal, 3) the treatment of adult patients with eosinophilic granulomatosis with polyangiitis, 4) the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome for ≥6 months without an identifiable non-hematologic secondary cause.

After the conclusion of the Phase 1 study Bio-Thera plans to run a global Phase 3 study and request approval for all available indications at the time of filing the BLA/MAA with NMPA, FDA, EMA and other regulatory bodies around the world.

Bio-Thera Solutions is developing several additional biosimilar products for the global market including biosimilar versions of Avastin®, Actemra®, Cosentyx®, Simponi® and Stelara®. QLETLI®, a biosimilar to Humira®, and Pobevcy®, a biosimilar to Avastin®, are approved by the NMPA and being commercialized in China.

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. A leader in next generation antibody discovery and engineering, the company has advanced six candidates into late-stage clinical trials and has two approved products, QLETLI® and POBEVCY® in China. In addition, the company has multiple promising candidates in early clinical trials and IND-enabling studies, focusing on immuno-oncology, ADC targeted therapies, autoimmune diseases, and other severe and emerging unmet medical needs. For more information, please visit www.bio-thera.com/en/ or follow us on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).

Cautionary Note Regarding Forward-Looking Statements

This news release contains certain forward-looking statements relating to BAT2606 or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing "could," "may," "should," "will," "would," "anticipate," "believe," "plan," "promising," "potentially," or similar expressions. They reflect the company's current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions, and are not a ensure of future performance or developments. genuine results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies, for example, the development processes could be lengthy and high in vitro affinity may not translate to desired results in vivo or successful clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company's financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company's views or otherwise.

1 Nucala® is a registered trademark of GSK plc
2 Avastin® is a registered trademark of Genentech, Inc
3 Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corporation
4 Cosentyx® is a registered trademark of Novartis AG
5 Simponi® is a registered trademark of Johnson & Johnson Corporation
6 Stelara® is a registered trademark of Johnson & Johnson Corporation
7 QLETLI® is a registered trademark of Bio-Thera Solutions, Ltd
8 Humira® is a registered trademark of AbbVie Biotechnology Ltd
9 Pobevcy® is a registered trademark of Bio-Thera Solutions, Ltd

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Thu, 13 Oct 2022 21:28:00 -0500 text/html https://www.benzinga.com/pressreleases/22/10/b29265177/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimil
101-500 exam dump and training guide direct download
Training Exams List